Royal Bank of Canada Purchases 39,553 Shares of Artivion, Inc. $AORT

Royal Bank of Canada raised its position in shares of Artivion, Inc. (NYSE:AORT) by 73.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 93,676 shares of the company’s stock after purchasing an additional 39,553 shares during the quarter. Royal Bank of Canada owned 0.19% of Artivion worth $3,430,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Artivion in the third quarter worth $27,000. Rockefeller Capital Management L.P. lifted its stake in shares of Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after buying an additional 399 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock valued at $43,000 after buying an additional 563 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the period. Finally, KBC Group NV bought a new position in Artivion in the 4th quarter worth $65,000. 86.37% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $20.70, for a total transaction of $910,820.70. Following the completion of the transaction, the senior vice president directly owned 60,259 shares of the company’s stock, valued at approximately $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jean F. Holloway sold 977 shares of the firm’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares of the company’s stock, valued at $5,245,521.82. This represents a 0.53% decrease in their position. The SEC filing for this sale provides additional information. 6.30% of the stock is currently owned by corporate insiders.

Artivion Stock Performance

Shares of NYSE AORT opened at $29.22 on Friday. The company has a market cap of $1.42 billion, a P/E ratio of -417.33 and a beta of 1.25. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47. The firm’s fifty day moving average is $24.28 and its two-hundred day moving average is $30.59.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The business had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. As a group, analysts anticipate that Artivion, Inc. will post 0.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AORT. Needham & Company LLC reissued a “buy” rating and set a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Citigroup reaffirmed a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Citizens Jmp cut their target price on Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research report on Friday, May 8th. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday. Finally, Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a report on Saturday. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Artivion has a consensus rating of “Moderate Buy” and a consensus target price of $44.67.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.